<DOC>
	<DOCNO>NCT02335346</DOCNO>
	<brief_summary>The purpose study assess safety efficacy duloxetine participant osteoarthritis knee pain . The study last 1 year .</brief_summary>
	<brief_title>An Extension Study Duloxetine Osteoarthritis Knee Pain ( Extension F1J-JE-HMGX , NCT02248480 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>( Consecutive Participants ) Participants complete 15week treatment precede study HMGX . ( New Participants ) Participants present osteoarthritis ( OA ) base American College Rheumatology ( ACR ) classification idiopathic OA knee . Have pain ≥14 day month 3 month prior study entry . Have score ≥4 BPI average pain score start study . ( Consecutive New Participants ) Females childbearing potential must test negative ( ) pregnancy test . ( New Participants ) Participants previous diagnosis psychosis , bipolar disorder , schizoaffective disorder . Participants major depressive disorder determine use depression module MiniInternational Neuropsychiatric Interview ( M.I.N.I. ) . Participants receive intrarticular hyaluronate steroid , joint lavage , invasive therapy knee past 1 week . Participants knee arthroscopy index knee within past year joint replacement index knee osteotomy time . Participants prior synovial fluid analysis show white blood cell ( WBC ) ≥2000 cubic millimeter ( mm3 ) indicative diagnosis OA . Participants history one medical allergy . Are nonambulatory require use crutch walker . Have frequent fall could result hospitalization could compromise response treatment . Have history drug abuse dependence within past year , include alcohol exclude nicotine caffeine . Have positive urine drug screen substance abuse exclude medication . Have receive administration another investigational drug within 30 day prior enrollment . Have previous exposure duloxetine completed/withdrawn study investigate duloxetine . ( Consecutive New Participants ) Participants serious cardiovascular , hepatic , renal , endocrine , respiratory , hematologic illness , peripheral vascular disease , medical condition neuropsychiatric condition clinically significant laboratory abnormality electrocardiographic abnormality . Participants alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) high 100 international unit per liter ( IU/L ) total bilirubin high 1.6 milligrams/deciliter ( mg/dL ) . Participants serum creatinine level high 2.0 mg/dL , renal transplantation receive renal dialysis . Participants diagnosis inflammatory arthritis ( , rheumatoid arthritis ) autoimmune disorder ( exclude inactive Hashimoto 's thyroiditis Type 1 diabetes ) . Participants uncorrected thyroid disease , uncontrolled narrowangle glaucoma , history uncontrolled seizure , uncontrolled poorly control hypertension . Participants end stage bone disease surgery plan trial index joint . Participants treat monoamine oxidase inhibitor ( MAO ) within 14 day prior baseline , potential need use MAO inhibitor study within 5 day discontinuation investigational drug . Participants answer 'yes ' question active suicidal ideation/intent/behaviors occur within past month ( ColumbiaSuicide Severity Rating Scale , suicide ideation sectionquestions 4 5 ; suicidal behavior section ) . Have primary painful condition may interfere assessment index joint , i.e. , knee . Pregnant participant , female participant wish pregnant clinical study period , participant breastfeed ; male participant wish pregnancy partner . Participants use appropriate contraceptive method want use start study one month end administration investigational drug . Considered inappropriate participation study medical reason investigator .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>